Introduction
Neutrophils are the most abundant WBC type, comprising up to 40-60% of the leukocytes. They have an essential role in the innate immune response to bacterial and fungal infections; however, they are also known as a major contributor to tissue damage in inflammatory diseases, such as RA, vasculitis, cystic fibrosis, chronic lung disease, and inflam matory bowel disease [1] . Tight regulation of both neutrophil numbers and recruitment to sites of inflammation is critical in maintaining a balanced immune response, and G-CSF has long been described as a key regulator of neutrophil homeostasis [2] .
G-CSF is a hemopoietic cytokine first identified for its role in granulopoiesis [3] and is also recognized as a proinflammatory mediator of mature neutrophil activation and function. G-CSF binds to the homodimeric G-CSFR, which is expressed primarily on neutrophils and hemopoietic progenitors. G-CSF binding to G-CSFR activates the associated JAK1 and JAK2 protein tyrosine kinases, which, in turn, phosphorylate the transcription factor STAT3 leading to activation, with additional weak activation of STAT1 and STAT5 [4] .
Under steady-state conditions, G-CSF serum levels are near or below detection limits [5] ; however, serum G-CSF increases during infection, resulting in increased neutrophil numbers required for clearing the pathogen [6, 7] . Although increases in serum G-CSF and the corresponding elevation of neutrophil numbers are important for the clearance of pathogens, they are also associated with several inflammatory diseases. It is well recognized that neutrophils contribute to the pathogenesis of a number of human diseases, including chronic obstructive pulmonary disease, RA [8] , Sjögren's syndrome [9] , Behçet's disease [10] , and inflammatory arthritis [11, 12] (reviewed in Wright et al. [13] ). In addition to peripheral neutrophilia observed in inflammatory conditions, neutrophil numbers are also increased at the sites of inflammation, as demonstrated by infiltration into the joints of patients with RA [11] . Sustained neutrophil activity and continued neutrophil recruitment at sites of inflammation exacerbates tissue damage through secretion of inflammatory mediators, such as IL-8, IL-1, IL-6, and TNF-a [14, 15] ; release of reactive oxidative species [16] ; and release of neutrophil granule proteins [17] [18] [19] .
Current treatment options for many inflammatory conditions involve the use of broad-based therapeutics, such as corticosteroids, nonsteroidal anti-inflammatory drugs, and general immunosuppressives, as well as more specific biologic therapeutics, such as TNF-a inhibitors. Although these therapies do not target neutrophils directly, they inhibit neutrophil function indirectly, including reducing cytokine and cytotoxic granule release and dampening neutrophil oxidative burst, thus reducing inflammation (reviewed in Wright et al. [13] ). A novel way to target the damaging effects caused by neutrophils during inflammatory conditions may be to target the neutrophils themselves via their main regulator G-CSF. Studies in mice with genetic deletion of either G-CSF (G-CSF 2/2 ) or G-CSFR (G-CSFR 2/2 ) have shown that abolition of G-CSF signaling provides protection from the development of inflammation. We have previously reported that G-CSF 2/2 mice are resistant to collagen-induced arthritis, an autoimmune model of inflammatory arthritis, and WT mice treated with anti-G-CSF mAbs also had substantially reduced collagen-induced arthritis, even when the anti-G-CSF mAb was administered after the onset of joint inflammation [20] . Recent work with a collagen Ab-induced arthritis model has shown that targeting the G-CSFR with an anti-G-CSFR mAb can halt the progression of established disease and prevent neutrophil accumulation in the joints without rendering the animals neutropenic [21] . Further studies in experimental autoimmune encephalitis and experimental autoimmune uveitis mouse models show that, compared with WT mice, G-CSF 2/2 mice had reduced neutrophil numbers in both the periphery and at sites of pathology and were markedly protected from CNS inflammation and disease progression. Similar results were observed in WT mice treated with a neutralizing anti-G-CSF mAb [22] . To further understand the therapeutic potential of a G-CSF signaling blockade, we developed a mAb antagonist to human G-CSFR (CSL324), which prevents the binding of G-CSF and subsequently inhibits G-CSF signaling. In this study, we show that administration of CSL324 to NHPs can inhibit G-CSF-mediated pSTAT3 signaling without inducing neutropenia or affecting neutrophil functions. In addition, we demonstrate that the anti-G-CSFR Ab is effective in reducing G-CSF-mediated neutrophilia when administrated either before or after G-CSF administration. Collectively, these data demonstrate that complete neutralization of the G-CSFR is safe and well tolerated in NHPs, suggesting that G-CSFR blockade may be a viable therapeutic strategy for reducing neutrophil numbers and the subsequent proinflammatory effects of neutrophils in chronic inflammatory disease.
MATERIALS AND METHODS

Ab development
The Dyax phagemid FAB-310 library (Dyax Corp., Cambridge, MA, USA) was screened for phagemids that bound the recombinant extracellular domain of human G-CSFR fused to the Fc region of human IgG1 immobilized on Dynabeads M-280 streptavidin (Thermo Fisher Scientific, Waltham, MA, USA) by biotin-anti-human Fc Ab capture (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Phage selection was performed, as described previously [23] . Before selection the phage input was depleted for nonspecific binders to either streptavidin or Fc by 5 consecutive incubations with a 1:1 mixture of streptavidin beads per se or coated with an irrelevant human IgG Ab via biotin anti-human Fc capture. Three rounds of selection were performed by incubating the depleted phage input with decreasing concentrations of immobilized hßc-Fc (15, 10, and 5 mg) in 2% milk/PBST (0.1% Tween-20) for 20 min at RT. Selected phage was amplified in log phase Escherichia coli TG1 cells, and the selected Fab-phagemids were rescued by superinfection with M13K07 helper phage before purification using standard protocols [24] . Individual clones were picked after the second and third round of selection, and the Fab cassettes and light chains were PCR-amplified and sequenced essentially as described [23] . Competitive phage ELISA was used to screen for high-affinity clones, which were reformatted as full-length Abs and further assessed using biochemical and cell-based assays.
Biacore mAb binding analysis via surface plasmon resonance
An anti-human Ig Ab [goat anti-human IgG (g) mouse adsorbed, catalog No. H10500; Thermo Fisher Scientific] was chemically immobilized on a CM-5 sensor surface using amine coupling chemistry to 8000-12,000 resonance units. The immobilized Ab was then used to capture anti-G-CSFR mAbs from solution at 0.3 mg/ml for 120 s. Soluble G-CSFR proteins (WT or mutant G-CSFR proteins as required) were then injected over the captured mAbs at a number of different concentrations between 0 and 250 nM (in duplicate). Injection was performed for 10 min, and dissociation was monitored for a further 30 min. After each cycle, the surface was regenerated with a 90-s injection of 100 mM H 3 P0 4 . Binding curves were reference subtracted, and the buffer was blanked before fitting to a 1:1 kinetic model. Assays were performed at 25°C when assessing binding of CSL324 to the various mutant G-CSFR proteins and at both 25 and 37°C when assessing binding of CSL324 to WT human G-CSFR.
Alanine mutagenesis
The specific binding site of the Ab to human G-CSFR was determined by alanine scanning mutagenesis [25] . Alanine point mutants of residues in, and proximal to, the previously identified cytokine-binding site on the human G-CSFR were generated, and soluble forms of the WT and the mutant receptors were produced. Using SPR, the binding affinities of CSL324 to these mutants, relative to WT, was determined, with the results demonstrating that CSL324 binds a number of key residues important in the interaction of G-CSF to the G-CSFR and is, therefore, able to compete directly with G-CSF for binding to the receptor.
NHP studies
Studies in cynomolgus monkeys, representing the only pharmacologically relevant animal species for the humanized mAb CSL324, were conducted at either Charles River Laboratories (Edinburgh, United Kingdom), Envigo [Huntingdon Life Science (Huntingdon, Cambs, United Kingdom)], or the Monash Animal Research Platform (Victoria, VIC, Australia) in accordance to standard operating procedures, after approval from the Institutional Animal Care and Use Committee and the European Convention on Animal Care. Naive cynomolgus monkeys were administered CSL324 at various doses via i.v. infusion (0, 0.01, 0.1, 0.3, 1, 3, or 10 mg/kg for a single dose or 3 doses of 10 mg/kg fortnightly). Select animals in a second single-dose study were also administered s.c. 5 mg/kg neupogen (rG-CSF) twice daily for 3 d or a single s.c. dose of 100 mg/kg Neulasta (pegylated rG-CSF) on d 1 of the study to determine the ability of CSL324 to dampen G-CSF-mediated neutrophilia. Peripheral blood was collected at various times for laboratory assays of neutrophil number and function. Blood samples were sent to an external veterinary pathologist for a full blood examination, including neutrophil numbers, or were assessed using a Bayer Advia 120 hematology analyzer (Bayer Leverkusen, Germany) during the 12-wk, repeat-dose study. Select animals in the repeat-dose study were administered 25 mg/kg leukine (rGM-CSF) twice daily on d 30, 31, and 32 to ensure CSL324-treated animals maintained responsiveness to GM-CSF-induced neutrophil mobilization. In the subsequent, repeat-dose study conducted in compliance with Good Laboratory Practice standards, cynomolgus monkeys (n = 3F/3M per treatment group) received weekly administration of CSL324 via slow bolus i.v. injection at doses of 0, 1, 10, 30, and 100 mg/kg for 12 wk. The extent of systemic exposure and pharmacokinetic profile of CSL324 was determined after the first (d 1) and last (d 78) dose. In addition, neutrophil numbers and function were monitored pretreatment, and 24 h after various doses.
Primary cells
Peripheral blood from healthy donors was obtained with informed consent from the Australian Red Cross Blood Service in lithium-heparin tubes. Peripheral blood was also collected from cynomolgus monkeys in lithiumheparin tubes. Assays were completed using whole blood or red-cell lysed blood. Red cells were lysed with ammonium chloride (StemCell Technologies, Tullamarine, VIC, Australia) for 10 min at RT. WBCs were then counted using trypan blue and a hemocytometer. For all flow cytometric assays, neutrophils were identified as SSC high CD11b + and CD49d
2
. For phenotype experiments, nonviable cells were excluded by fluorogold staining (Thermo Fisher Scientific).
Serum CSL324 and G-CSF determination
Serum CSL324 levels were determined from CSL324 or saline-treated animals; 96-well MaxiSorb plates were coated with 0.5 mg/ml hG-CSFR and coated for 12-24 h. Unbound protein was removed, and the plate was washed 3 times before 250 ml/well of Superblock Blocking Buffer (Pierce Biotechnology, Rockford, IL, USA) was added for 2-4 h. Blocking buffer was removed, the plate was washed, and test samples, standards, and controls were added for 60 min at RT. After washing, Goat anti-human IgG HRP (Bio-Rad Laboratories, Hercules, CA, USA) was added for 60 min at RT followed by TMB Microwell peroxidase substrate solution (KPL, Gaithersburg, MD, USA). This reaction was stopped with 1 M phosphoric acid, and plates were read at 450 nm on a microtiter plate reader. Alternatively, a SULFO-TAG-labeled detection Ab and an ECL chemical luminescence plate reader (MSD Sector Imager 6000; Meso Scale Diagnostics, Rockville, MD, USA) were used for estimation of CSL324 serum levels during the 12-wk, repeat-dose study.
Serum G-CSF was determined from CSL324-or saline-treated animals using an hG-CSF immunoassay (R&D Systems, Minneapolis, MN, USA), per manufacturer's instructions. Briefly, diluted serum samples and controls were added to precoated microplate strips for 2 h at RT. Wells were washed 3 times, then conjugate reagent was added for 2 h. Wells were washed, then substrate solution was added for 20 min RT. The reaction was stopped with a stopping solution, and the plate was read at 450 nm within 30 min on a microtiter plate reader.
CSL324 competitive-binding assays
WBCs from healthy donors or cynomolgus monkeys were cultured with titrated concentrations of unlabeled CSL324 in the presence of 1/10 hFcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany). The unoccupied G-CSFR was bound with 50 ng/ml hG-CSF-biotin (PeproTech, Rocky Hill, NJ, USA) conjugated with Thermo Fisher Scientific EZ-Link Sulfo-NHS-LC-biotin, detected with streptavidin-PE (554061; BD Biosciences, Franklin Lakes, NJ, USA). The background level of binding was determined by incubation with 1003 M excess, unlabeled hG-CSF and subsequent incubation with G-CSF-biotin and streptavidin-PE. WBCs were also incubated with titrated concentrations of hG-CSF, and the unoccupied G-CSFR was then detected with 1 mg/ml CSL324-PE. Background levels were determined by incubation of WBCs with a 1003 M excess of CSL324 and then subsequent incubation with CSL324-PE. All binding was measured by flow cytometry of gated neutrophil populations (CD11b + CD49d 2 ) and determination of PE geometric MFI.
pSTAT3 signaling
The in vitro induction of STAT3 signaling in human and cynomolgus neutrophils was measured by incubating WBCs prelabeled with CD11b-PECY7 (557743; BD Biosciences) and CD49d-APC (559881; BD Biosciences) with various doses of CSL324 (0.0001-8.33 mg/ml) and incubating for 20 min at 37°C before stimulating with various doses of hG-CSF (0.0195-80 ng/ml; PeproTech) or cynomolgus G-CSF (0.0195-80 ng/ml, produced in house) for 30 min. Cells were then fixed with 4% paraformaldehyde (BD Biosciences) and permeabilized with methanol before being stained the following day with anti-pSTAT3 (pY705) PE (BD 612569) and analyzed by flow cytometry. STAT3 signaling was also measured in WBCs from animals treated with CSL324 or saline by surface labeling with CD11b and CD49d to identify neutrophils, then stimulating WBCs in vitro with various doses of hG-CSF (0.1-500 ng/ml) for 30 min at 37°C. Cells were then fixed with 4% paraformaldehyde and permeabilized with methanol before being stained the following day with anti-pSTAT3 (pY705) PE and analyzed by flow cytometry.
Neutrophil survival
Neutrophils were enriched by firstly layering whole blood on Ficoll-Paque Plus (GE Healthcare, Waukesha, WI, USA) and centrifuging at 1000 g for 10 min at RT. The pellet was resuspended in HBSS in twice the original volume, and dextran T-500 was added for a final concentration of 1%. The RBCs were allowed to settle for 1 h at RT, and the polymorphonuclear, leukocyte-rich supernatant was collected and diluted 1:2 with HBSS and centrifuged at 300 g for 10 min at 4°C. The polymorphonuclear leukocyte pellet was gently resuspended in HBSS and washed twice to remove traces of dextran. Enriched neutrophils were cultured in a 96-well plate at 1 3 10 5 cells/well in IMDM with 10% FCS in the presence or absence of titrated CSL324 and 5 ng/ml hG-CSF for 48 h. Cell viability was determined with a WSTI survival assay (Roche Diagnostics USA, Indianapolis, IN, USA) and read at 450 nm.
Colony-forming assay
For the CFU assay, CD34 + bone marrow cells or cord blood cells (StemCell Technologies) were seeded at 1.5 3 10 3 cells/35-mm dish in IMDM containing 1% methylcellulose (MethoCult H4534 Classic; StemCell Technologies) supplemented with 30% FCS, 1% BSA, 10 ng/ml human stem cell factor (PeproTech), and 10 ng/ml hG-CSF (PeproTech). Cultures were incubated at 37°C in a humidified atmosphere of 5% CO 2 for 14 d; after which, colonies were enumerated.
Phagocytosis assay
Samples from CSL324-or saline-treated animals were used to investigate the effects of CSL324 on phagocytosis of neutrophils using a pHrodo Red E. coli bioparticles conjugate (Thermo Fisher Scientific) per the manufacturer's instructions. Briefly, whole blood from each animal was incubated with E. coli bioparticles, the RBCs were then lysed, and the WBCs were surface stained with CD11b and CD49d before being washed and immediately acquired by flow cytometry. Phagocytosis was determined by gating on the CD11b 
Oxidative burst
The oxidative burst of neutrophils from NHPs treated with CSL324 or saline was investigated using DHR (Thermo Fisher Scientific). WBCs were incubated with 2.5 mM DHR in PBS for 10 min at 37°C before being stimulated with 50 ng/ml PMA (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37°C. WBCs were then surface stained for CD11b and CD49d, washed, and fixed with 1% formaldehyde before being acquired by flow cytometry. , and expression of the different markers was measured by MFI.
Neutrophil phenotype
Flow cytometry and data analysis
All flow cytometry was performed on a Canto II (BD Biosciences) or an LSR Fortessa (BD Biosciences) cell analyzer, and data were analyzed with FlowJo software (version 9; Tree Star, Ashland, OR, USA). Data were plotted, and statistical analysis performed with Prism software (version 6; GraphPad Software, La Jolla, CA, USA). For the 12-wk dosing study, maximum serum concentrations of CSL324 (C max ) and serum concentrations at 168 h postdose (C 168 ) were the observed values. Areas under the serum CSL324 concentration-time curves within a 168-h dosing interval (AUC 168 ) were estimated with the linear trapezoidal rule. C max and AUC 168 values, taken as indices of systemic exposure, were adjusted for dose and subjected to ANOVA, with dose level, sex, day of sampling, and their interactions as factors in the analysis.
RESULTS
CSL324 binds human and cynomolgus G-CSFR and is a competitive antagonist of G-CSF binding
To identify neutralizing Abs against the hG-CSFR, a semisynthetic hFab phage library with a diversity of 10 10 was screened for clones that bound hG-CSFR and could be eluted after addition of G-CSF ligand. Fabs were assessed by ELISA against three criteria: 1) their ability to bind G-CSFR, 2) their ability to compete with G-CSF for binding to the G-CSFR, and 3) their ability to crossreact with the cynomolgus G-CSFR. Fabs of interest were expressed as whole, fully human IgG4 Abs, incorporating the Ser-241 to Pro hinge stabilization mutation, and further characterized in a variety of primary cell assays for potency and their affinities for human and cynomolgus G-CSFR determined by SPR. The Ab with the highest affinity for hG-CSFR [K d = 1.37 6 0.07 nM (means 6 SD); n = 8] and cynomolgus G-CSFR [K d = 0.419 6 0.009 nM (means 6 SD); n = 4] was altered to match the closest human germline sequence and the resulting Ab was designated CSL324. Because primary neutrophils are the predominant cell subset expressing G-CSFR [26, 27] , relative binding of CSL324 to human and cynomolgus neutrophils, in reciprocal binding experiments, was conducted. CSL324-bound G-CSFR on both human and cynomolgus neutrophils. as detected by flow cytometry (Fig. 1A) and competed for G-CSF binding in a dosedependent manner (Fig. 1B and C) . Moreover, G-CSF also competed for CSL324 binding in human or cynomolgus neutrophils ( Fig. 1D and E) .
Residues in G-CSFR that contribute to CSL324 binding were identified by Ala scanning mutagenesis. Because CSL324 can compete with G-CSF for binding, Ala point mutants of residues in, and proximal to, the previously identified cytokine-binding site on the hG-CSFR were generated [28] . Soluble forms of the mutant receptors and WT receptor were produced, and the binding affinities of CSL324 to mutant and WT receptors were determined by SPR. Binding affinities of CSL324 to mutant receptors relative to the WT receptor is shown in Fig. 1F , with residues having the greatest effect on CSL324 binding shown on the G-CSFR structure (Fig. 1G ). The results demonstrate that CSL324 interacts with residues important for G-CSF binding to G-CSFR, suggesting that CSL324 is a competitive antagonist of G-CSF binding.
CSL324 is a potent inhibitor of G-CSF activity
After G-CSF binding to the G-CSFR, JAK kinase family members become activated and subsequently phosphorylate STAT3 and, to a lesser extent, STAT5 and STAT1 [4] . Therefore, pSTAT3 was used to determine the capacity of CSL324 to effectively block G-CSFR signaling. Human G-CSF induced a dose-dependent activation of STAT3 in human neutrophils that was potently inhibited by CSL324 ( Fig. 2A  and B) . Activation of STAT3 could be induced by either human or cynomolgus G-CSF in cynomolgus neutrophils (Fig. 2C) . This was likely due to the high sequence homology between human and cynomolgus G-CSFR (94.4% amino acid identity) and G-CSF (93.0% amino acid identity). CSL324 inhibited both human (Fig. 2D ) and cynomolgus (data not shown) G-CSF-induced pSTAT3 in a dose-dependent manner, with similar potency. G-CSF-induced signaling provides neutrophils with survival signals, promotes colony formation, and promotes neutrophil proliferation and maturation [29, 30] . The optimum G-CSF concentration to sustain neutrophil survival, measured at 48 h in vitro, was determined (5 ng/ml; data not shown) and CSL324 was shown to potently inhibit that survival response in a dose-dependent manner (Fig. 2E) . In addition, CSL324 inhibited G-CSF-induced neutrophilic colony formation (CFU-G) from hematopoietic progenitor cells, as assessed with cord blood cells and CD34 + stem cells cultured with stem cell factors and G-CSF for 14 d (Fig. 2F) .
A single dose of CSL324 reduces G-CSF-induced neutrophilia in cynomolgus macaques without inducing neutropenia
To determine the effect of neutralizing the G-CSFR on neutrophils in vivo, CSL324 was administered to cynomolgus macaques as the only cross-reactive, pharmacologically relevant animal species. Naive macaques were given a single i.v. administration of CSL324 (0.1-10 mg/kg). Pharmacokinetic analysis showed that serum CSL324 levels were maintained above 0.3 mg/ml for 14 d in animals administered at 1, 3, and 10 mg/kg, with lower doses being eliminated within 4 d postinfusion (Fig. 3A) . Administration of CSL324, at doses $0.3 mg/kg, resulted in an increase of serum G-CSF, which returned to predose levels with waning drug concentrations (Fig. 3B) . No increase in serum G-CSF was observed at the 0.1 mg/kg dose. A transient increase in neutrophil numbers was observed with all doses of CSL324 at 1 h after administration (Fig. 3C) , which returned to baseline by 24 h. A similar increase in neutrophil numbers was observed at d 7 for all doses, with the exception of the high-dose groups. Because increased neutrophil numbers were also observed in control animals (saline alone), that was likely a response to infusion. Interestingly, although neutrophil numbers fluctuated over the 28 d, neutropenia was not observed at any point, and neutrophils remained within the reported reference range [1% (1.56 3 10 3 /ml) 2 99% (16.68 3 10 3 /ml); numbers provided from Huntingdon Life Science, contract research organization facility; n = 2359 male and female cynomolgus macaques of Vietnamese origin]. We next investigated the ability of a single dose of CSL324 to reduce G-CSF-induced neutrophilia when dosed either before or after s.c. administration of G-CSF. A single i.v. infusion of CSL324 (0.01, 0.1, 1, 3, or 10 mg/kg) was given, followed by 6 doses of G-CSF (5 mg/kg) over a 3-d period. G-CSF induced a rapid increase in neutrophil numbers that was maintained for the duration of dosing. Pretreatment with CSL324 prevented G-CSF-mediated neutrophilia in a dose-dependent manner, with doses at and above 1 mg/kg completely suppressing the increase in neutrophil numbers at all times (Fig. 4A) . The 0.1 mg/kg dose of CSL324 delayed the onset of neutrophilia by 36 h, whereas no suppression was observed at the 0.01 mg/kg dose. Neutrophil numbers remained above baseline levels for all doses of CSL324, including doses that completely suppressed G-CSF-induced neutrophilia.
We also tested whether CSL324 could reverse pre-established neutrophilia induced by G-CSF. Neutrophilia was induced by a single dose of pegylated G-CSF, with the peak of the neutrophilia observed 12 h after G-CSF administration (Fig. 4B ). An i.v. infusion of CSL324 (10 mg/kg) was administered at the peak of G-CSF-induced neutrophilia, and although CSL324 was able to completely and rapidly neutralize G-CSF-mediated neutrophilia, it again did not induce neutropenia (Fig. 4B ). These data show that the G-CSFR blockade by CSL324 effectively prevented G-CSF-induced neutrophilia and reduced preestablished neutrophilia without leading to neutropenia.
Repeat dosing of CSL324 does not induce neutropenia in NHPs
We next determined the effect of prolonged exposure of CSL324 on neutrophil function and neutrophil numbers. Animals received i.v. infusion of CSL324 (10 mg/kg) or saline control on d 1, 15, and 29, and peripheral blood was collected at various points for pharmacokinetic analysis (Fig. 5A) . One animal (FF156) had an attenuated CSL324 PK profile after the second and third doses indicative of antidrug Abs and was not included in the analysis (Fig. 5B) . A mean trough level of .30 mg/ml CSL324 was maintained throughout the interdose intervals and for at least 2 wk (d 43) after the last dose. Neutrophil numbers remained within reference range of 1.56-16.68 3 10 3 /ml in both the salineand CSL324-treated groups for the duration of the study (72 d), and no evidence of neutropenia was observed in any animal at any point (Fig. 5C) . No immature forms of neutrophils were detected in any animals during the study (data not shown).
We determined the ability of CSL324 to block G-CSFR after i.v. administration of CSL324 in NHPs by measuring G-CSF-induced pSTAT3 signaling ex vivo in blood samples at various times after infusion. Before infusion, all animals responded comparably to G-CSF stimulation with an EC 50 of ;1 ng/ml and an EC max of ;10 ng/ml (predose d-6; Fig. 5D ). On d 2 and 18, animals that received CSL324 Abs showed complete inhibition of G-CSF-induced pSTAT3 at both EC 50 and EC max concentrations (1 and 10 ng/ml), whereas salinetreated animals responded similarly to that of the predose times. These data show that i.v. administration of CSL324 at 10 mg/kg prevents G-CSF-mediated G-CSFR activation, which suggest that blood concentrations of CSL324 in vivo, are sufficient to block G-CSFR. Two weeks after the second dose (d 29), 4 of 5 CSL324-treated animals still showed complete inhibition of pSTAT3 when stimulated with G-CSF at either 1 or 10 ng/ml. GM-CSF-induced pSTAT5 signaling was unaffected by CSL324 treatment at any points (Supplemental Fig. 2) , demonstrating the specificity of this Ab and also suggesting that CSL324 does not alter the ability of neutrophils to respond to other stimuli. Interestingly, these data suggest that G-CSFR neutralization for #6 wk (42 d) does not result in neutropenia.
To determine whether higher doses of CSL324 and/or longer dosing times might affect neutrophil numbers, a 12-wk, repeat-dose study in cynomolgus monkeys was conducted. Animals received weekly i.v. administrations of CSL324 at dose levels of 1, 10, 30, and 100 mg/kg. The maximum serum CSL324 levels were seen at the first sampling time after dosing hG-CSF-induced pSTAT3 in NHP neutrophils is potently inhibited by CSL324 (graphs show MFI means 6 SE from n = 6 healthy donors or n = 6 cynomolgus monkeys measured over 3 independent experiments). (E) Neutrophils isolated from human peripheral blood were stimulated either with or without 5 ng/ml hG-CSF for 48 h, and viability was determined with the WSTI survival assay. Prior treatment of the neutrophils with titrated CSL324 inhibited G-CSF survival in a dose-dependent manner (graphs show percentage viability means 6 range from n = 2 healthy donors over 2 independent experiments). (F) CD34 + bone marrow or cord blood cells were cultured with 10 ng/ml hG-CSF and 10 ng/ml of human stem cell factor for 14 d and colonies were enumerated. Prior treatment with titrated CSL324 blocked colony formation in a dose-dependent manner (graphs show CFU-G means 6 range from n = 2 healthy donors over 2 independent experiments).
(0.25 h), as expected after i.v. administration (Supplemental Fig. 1A and B) , achieving mean C max levels up to 2390 mg/ml and AUC 0-168h of 184,000 mg 3 h/ml in animals treated with 100 mg/kg after the first dosing (d 1). During repeated dosing (once per week for 12 wk), animals were continuously exposed to CSL324 with C max and AUC 0-168h reaching their highest levels on d 78, indicating dose accumulation. As displayed in Supplemental Fig. 1C , systemic exposure increased approximately proportionately with increasing doses over the dose range of 1-100 mg/kg on both d 1 and 78, with no apparent sex differences. In the 1 mg/kg treatment group only, antidrug Abs against the humanized CSL324 mAb could be detected (data not shown) and resulted in increased mAb clearance and, therefore, lower exposure levels in 3 of 6 animals in that dose group.
Measurement of neutrophil numbers in peripheral blood throughout the 12-wk dosing period revealed no treatmentrelated effects (Supplemental Fig. 1D and E) . Individual male and female animals treated with doses of 30 or 100 mg/kg CSL324 and, to an extent, in the males treated with 10 mg/kg generally had lower than control neutrophil counts for most of the sampling occasions, but with no clear progression with time. Overall, most of the neutrophil counts in the males, and all the counts recorded for the females, were within the background range (1.56-16.68 3 10 3 /ml; means 6 SD 5.9875 6 3.16675 3 10 3 /ml). No treatment-related bacterial, viral, or fungal infections were observed. In addition, serial observations were conducted to assess the general health of the animals during the 12-wk dosing period, and there were no changes in body weight, food consumption, ophthalmic examination, electrocardiography, respiratory function, peripheral and bone marrow hematology, blood chemistry, and urinalysis. Terminal assessments were also conducted with organ weight and histology assessments, which showed no effects of CSL324 dosing, concluding that multiple doses of CSL324 were safe and well tolerated.
Neutrophils from CSL324-treated animals retain phagocytic and oxidative burst functions
In addition to its effects on neutrophil expansion and mobilization from the bone marrow, G-CSF also affects neutrophil trafficking at a steady state [31] and during inflammatory conditions [32] and can affect neutrophil viability and function in the periphery. To investigate the effect of G-CSFR neutralization on neutrophil function, we studied NHP blood ex vivo at several times after infusion of CSL324. First, we determined the phagocytic capacity of neutrophils from CSL324-treated animals. We observed no significant difference in the percentage uptake of phagocytosed E. coli bioparticles by neutrophils from animals before the dose or animals treated with CSL324 (10 mg/kg) or saline at any point after infusion (Fig. 6A) . This was also true for animals treated for up to 12 wk with weekly i.v. doses of 100 mg/kg CSL324 (data not shown). We next determined the ability of neutrophils to undergo oxidative burst/respiratory burst, which occurs when neutrophils encounter bacterial peptides or inflammatory mediators and is critical for killing bacteria [33] . Oxidation of the nonfluorescent probe DHR to fluorescent rhodamine was used to measure PMA-stimulated oxidative bursts [33] . Neutrophils from CSL324 (10 mg/kg) treated and control animals had similar inductions of oxidative burst when stimulated with PMA at predose and also at all times after infusion (Fig. 6B) . Similarly, even during repeated dosing over 12 wk, CSL324 did not affect the oxidative burst activity in NHP-derived granulocytes (data not shown). The effect of CSL324 on the activation status of neutrophils was further investigated by assessing both baseline and LPSinduced levels of the adhesion molecules CD11b and CD62L. Viable neutrophils from CSL324-treated (10 mg/kg) animals showed a similar activation phenotype to control animals when examined for CD11b and CD62L expression (Fig. 6C) . Expression of CD49d, CD35, and CD16 were also assessed, with no changes observed (data not shown). These data demonstrate that in vivo administration of CSL324, at doses sufficient to block G-CSF signaling, does not change the basal activation status of neutrophils. In addition, when stimulated ex vivo, neutrophils from the CSL324-treated animals were still responsive to LPS, as evidenced by the up-regulation of CD11b and down-regulation of CD62L (Fig. 6D) . LPS-induced neutrophil activation was similar in CSL324 and control groups and did not change over time. Together, these data suggest that blocking the G-CSFR does not abrogate the ability of neutrophils to become activated and respond to foreign stimuli.
DISCUSSION
In this study, we describe a fully human anti-G-CSFR Ab (CSL324) that is safe and well tolerated when administered to cynomolgus macaques and does not alter neutrophil number or function when given in either single or multiple doses; however, it is effective in reducing preestablished neutrophilia and preventing G-CSF-induced increases in peripheral neutrophil numbers.
Neutralizing mAbs directed against the hG-CSFR have not, to our knowledge, been previously described. To identify neutralizing anti-hG-CSFR Abs, we screened a semisynthetic hFab phage display library for clones that bound to the soluble ecto-domain of hG-CSFR. We isolated a Fab that bound both human and cynomolgus G-CSFR, which was subsequently engineered as a whole IgG4 Ab and designated CSL324. That Ab bound hG-CSFR with low nanomolar affinity and could directly compete with G-CSF binding to human and cynomolgus neutrophils. The previously published crystal structure of G-CSF bound to G-CSFR revealed residues important for G-CSF binding, including Leu-172, Tyr-173, His-238, and Arg-288 [28] . Mutagenesis of these residues in the hG-CSFR showed that they also contributed to CSL324 binding, suggesting that the epitope of CSL324 was shared with the G-CSF binding site. CSL324 also inhibited downstream signals provided by G-CSF, such as phosphorylation of STAT3 and subsequently prevented neutrophil survival and colony formation in vitro. To our knowledge, this is the first description of a mAb that binds hG-CSFR and neutralizes G-CSF signaling.
A single i.v. infusion of CSL324 ($1 mg/kg) both prevented G-CSF-induced neutrophilia and restored preestablished neutrophilia to baseline. Surprisingly, given that G-CSF is thought to be the major regulator of granulopoiesis and both G-CSF 2/2 and G-CSFR 2/2 mice have an ;70% reduction in peripheral blood neutrophils [34, 35] , CSL324 did not significantly reduce peripheral blood neutrophil numbers, which remained within the reference range over the study period. The only drug-induced change in basal neutrophil numbers was a dose-independent increase observed at 1 h after the dose. That fluctuation returned to predose levels by 4-24 h, with subsequent fluctuations remaining within the reference healthy range. The cause of CSL324-induced transient neutrophilia is unknown; however, because it is doseindependent, it may be a response to infusion rather than the drug per se. In addition to transient neutrophilia, CSL324 also resulted in a dose-dependent increase in serum G-CSF, which was likely due to blocking of receptor-mediated clearance of G-CSF, as previously reported [36] . The effect of G-CSFR blockade on peripheral neutrophil numbers was further examined by repeat dosing of CSL324 to cynomolgus macaques. We show that 3 doses of CSL324 (10 mg/kg) The first G-CSF administration was given 1 h after completion of CSL324 dosing. Blood was sampled at regular intervals for analysis of neutrophil numbers. At doses of 1, 3, and 10 mg/kg, CSL324 effectively inhibited G-CSF-induced neutrophilia across all times. At 0.1 mg/kg, the ability to control neutrophilia was lost after the third dose of G-CSF, whereas 0.01 mg/kg had no effect on G-CSF-induced neutrophilia (n = 3 animals/group, means 6 SE). (B) At 12 h after administration of a single dose of pegfilgrastim (clinical grade G-CSF, Neulasta; Amgen) (s.c. 100 mg/kg), a single i.v. dose of CSL324 (10 mg/kg) was administered to cynomolgus macaques, and blood was sampled at regular intervals for analysis of neutrophil numbers. Administration of CSL324 led to a dramatic decline in neutrophil numbers within the following 12 h without inducing neutropenia (n = 3 animals/ group, means 6 SE). Dotted lines identify the range for which neutrophil numbers are considered within reference range (see legend to Fig. 3 ).
administered i.v. at 14-d intervals maintained serum levels of the drug .30 mg/ml for 6 wk, and those levels were sufficient to completely neutralize G-CSF-induced STAT3 activation in most animals. Importantly, although we achieved blockade of the G-CSFR for the study duration, neutrophil numbers did not shift outside the reference range. Even after repeated dosing for up to 12 wk, with weekly doses up to 100 mg/kg, neutrophil numbers showed individual fluctuations but generally remained within the reference range. These data are consistent with our recent studies in WT mice, in which therapeutic administration of a neutralizing Ab against mouse G-CSFR resulted in only a slight reduction of peripheral neutrophil numbers [21] . Administering multiple doses of Ab risks developing ADAs, and that phenomenon is common in NHPs dosed with fully human Abs. Our analysis suggests that ADAs were present in some animals in our 12-wk study (data not shown); however, there were no associated effects on pharmacokinetic and pharmacodynamic readouts and no adverse events. Potential adverse events that can occur from ADA formation include reduced drug efficacy and adverse infusion reactions, including hypersensitivity reactions, aplasia, or thrombocytopenia manifestations [37] ; however, ADA formation is less common in humans administered fully human Abs because they are less immunogenic. Our current data in NHPs, and as previously shown in mice, demonstrate that neutralizing anti-G-CSFR Abs do not render animals neutropenic, in contrast to the reduction in neutrophils observed in G-CSF 2/2 and G-CSFR 2/2 mice. An explanation for the apparent discrepancy between steady-state neutrophil levels observed in G-CSF 2/2 and G-CSFR 2/2 mice, compared with animals treated with anti-G-CSFR Abs is that G-CSF may have a distinct role during development, compared with a less-significant role in adult animals with established neutrophil repertoires. Usually, neutrophils are derived from pluripotent stem cell progenitors and, upon stimulation with stem cell factors, GM-CSF, and G-CSF, they proliferate and Figure 6 . Circulating neutrophils retain key innate functions after repeat dosing with CSL324. (A) Whole blood from CSL324-treated (n = 5) and untreated control (n = 3) animals (see experimental schema in Fig. 5A ) was incubated with E. coli bioparticles to assess phagocytic capacity. There was no significant difference between the phagocytic capacity of neutrophils from CSL324-treated and untreated animals at predose and at d 2, 8, and 36 after CSL324 administration. Representative histograms are shown; control incubation at 4°C (shaded), test incubation at 37°C (black line). (B) Neutrophils from animals treated with CSL324 respond similarly to neutrophils from control-treated animals when stimulated with PMA. Oxidative burst was measured by examining the oxidation of DHR by flow cytometry (means 6 SE, control n = 3, CSL324 n = 5). Neutrophils from CSL324-treated animals have a similar activation phenotype (CD11b and CD62L) to neutrophils from control-treated animals, as determined by flow cytometry when examined without stimulation (C) or when stimulated in vitro with 20 ng/ml LPS for 24 h (D) (controls n = 3, CSL324 n = 5).
develop to form mature, segmented neutrophils in the bone marrow [38] , which are subsequently released into the blood in a regulated fashion to maintain homeostatic levels. In adult animals, G-CSF is important in promoting "emergency granulopoiesis," resulting in neutrophilia; however, the exact role of G-CSF in maintaining steady-state levels of neutrophils, as well as the homeostatic feedback loop that adjusts the marrow to supply the periphery in times of infection is not completely understood. Although G-CSF 2/2 and G-CSFR 2/2 mice have reduced neutrophil numbers [34, 35] , they do not suffer from spontaneous infections and have sufficient residual neutrophil numbers to mount a healthy neutrophilic response to Candida albicans and control that infection similarly to WT mice [39] . These data, together with our findings, suggest that there are G-CSF-independent pathways that contribute to basal granulopoiesis. One such pathway may be mediated by IL-6, with a number of clinical studies, showing that blocking IL-6 signaling results in a dose-dependent decrease in peripheral neutrophil counts that recover with waning drug levels [40] . Increases in serum G-CSF in response to infection are known to result in rapid neutrophil release from the bone marrow by altering expression of adhesion molecules [31] . In addition, inflammatory diseases, such as RA [8] , are associated with high levels of serum G-CSF that promote an increase in neutrophil numbers in the periphery and subsequent recruitment of neutrophils to sites of inflammation. Therapeutic depletion of granulocytes has been shown to be effective in treating inflammatory conditions in both mice and humans. Mice depleted of neutrophils are completely resistant to the inflammatory effects of autoreactive immunoglobulin from K/BxN mice, a model of RA that causes rapid, joint-specific inflammatory responses [41] . In humans, the efficacy of adsorptive granulocyte and monocyte apheresis has been reported for the treatment of many inflammatory conditions, such Reiter syndrome [42] , Crohn's disease [43] , and ulcerative colitis [44, 45] . Although crude, these methods demonstrate the positive effect that reducing neutrophil numbers can have on disease pathology. We suggest that CSL324 may offer a moretargeted approach to controlling neutrophil numbers in disease. We show that i.v. administration of CSL324, when dosed sufficiently to block G-CSFR signaling, prevents subsequent G-CSF-mediated neutrophilia. In addition, we demonstrate that established neutrophilia induced by s.c. administered G-CSF is effectively reversed with a single dose of CSL324. In both studies, CSL324 normalized G-CSF-induced neutrophilia without resulting in neutropenia. As G-CSFinduced neutrophilia does not mimic an inflammatory response in its entirety, an in vivo inflammatory model would be ideal to further validate the efficacy of the anti-G-CSFR Abs. However, because of limitations in NHP disease models, we have investigated the efficacy of an Ab against the mouse G-CSFR in the collagen Ab-induced arthritis mouse model of arthritis, and a similar reduction in peripheral neutrophilia was demonstrated [21] . The reduction in peripheral neutrophil levels correlated with a therapeutic effect of that Ab. Similar to our study in cynomolgus macaques, neutropenia was not observed and neutrophil numbers in the bone marrow remained unchanged. In the same study, the anti-mouse G-CSFR Ab ameliorated collagen Ab-induced arthritis and prevented neutrophil accumulation in the inflamed joints.
In addition to evaluating the effect of blocking the G-CSFR on neutrophil numbers, we also determined the effect of CSL324 on neutrophil function. Once bound to its receptor, G-CSF activates STAT3 through the membrane distal C-terminal region [46] and, to a lesser extent, STAT1 and STAT5, through its membrane-proximal cytoplasmic region [47] . STAT3 is known to have important regulatory activity in controlling neutrophil movement because mice deficient in STAT3 fail to elicit acute neutrophil mobilization from the bone marrow, exhibit suppressed accumulation of the immature granulocytic subpopulation, and have a skewed long-term mobilization response [48] . G-CSF is known to directly induce expression of CXCR2, a chemoattractant receptor on immature neutrophils, in a STAT3-dependent manner, thus enhancing their responsiveness to neutrophil chemoattractant MIP-2 [49] ; moreover, STAT3-deficient neutrophils are dramatically impaired in CXCR2-dependent chemotactic activity, suggesting that G-CSF signaling promotes neutrophil migration. We showed that administration of CSL324 to NHPs completely inhibited pSTAT3 signaling in neutrophils, as demonstrated by ex vivo G-CSF stimulation. G-CSF stimulation also enhanced neutrophil phagocytosis, oxidative burst, and bactericidal killing [50] . We showed, through various ex vivo functional assays, that complete neutralization of the G-CSFR had no effect on neutrophil phagocytosis of E. coli particles or on PMA-stimulated oxidative bursts, both of which are important for the killing and degradation of internalized bacteria [51] . PMA is a potent stimulus of oxidative bursts, and a potential effect of CSL324 on less potent, more physiologically relevant stimuli cannot be excluded.
Our data suggest that, in inflammatory conditions that are neutrophilic in nature, anti-G-CSFR therapy will reduce neutrophil numbers and may limit neutrophil migration to sites of inflammation, thus potentially alleviating tissue damage and inflammatory symptoms without compromising basic neutrophil function. These data provide further support for anti-G-CSFR therapy for the treatment of various neutrophil-driven inflammatory conditions. AUTHORSHIP K.S.-I. and K.M. planned, conducted, analyzed in vivo and in vitro experiments and wrote the manuscript; K.E., D.K., and S.R. planned, conducted, and analyzed the production of the CSL324 Ab; E.H. planned and analyzed the NHP in vivo experiments; D.M., M.H., V.S., H.H., and H.B. planned, conducted, and analyzed various in vivo and in vitro experiments; N.W. contributed to the manuscript preparation; S.B., A.N., and A.A. contributed to study conception, design, and experimental performance and contributed to the manuscript preparation. their technical assistance, Con Panousis (CSL Ltd), Michael Wilson (CSL Ltd), Steve Dower (CSL Ltd) and Eugene Maraskovsky (CSL Ltd) for their guidance and supervision and Ian Campbell (CSL Ltd) for helpful discussion.
